Spots Global Cancer Trial Database for relapsed or refractory acute myeloid leukemia (aml)
Every month we try and update this database with for relapsed or refractory acute myeloid leukemia (aml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | NCT03218683 | Relapsed or Ref... | AZD5991 AZD5991 + Venet... | 18 Years - 85 Years | AstraZeneca | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | NCT05345938 | Relapsed or Ref... | Mitoxantrone Hy... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05241093 | Relapsed or Ref... | HYML-122; cytar... | 18 Years - | Tarapeutics Science Inc. | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05241093 | Relapsed or Ref... | HYML-122; cytar... | 18 Years - | Tarapeutics Science Inc. | |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05241106 | Relapsed or Ref... | HYML-122 | 18 Years - | Tarapeutics Science Inc. | |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05241106 | Relapsed or Ref... | HYML-122 | 18 Years - | Tarapeutics Science Inc. | |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | NCT02074839 | Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic... | AG-120 | 18 Years - | Servier | |
| A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation | NCT04691648 | Acute Myeloid L... | Gilteritinib Ex... | 18 Years - | Astellas Pharma Inc | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | NCT05345938 | Relapsed or Ref... | Mitoxantrone Hy... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | NCT05345938 | Relapsed or Ref... | Mitoxantrone Hy... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
